Skip to main content
Hauptrubriken
CME Facharzt-Training Webinare Zeitschriften Bücher e.Medpedia Podcast
Service
Jobbörse Info & Hilfe
Fachgebiete
Anästhesiologie Allgemeinmedizin Arbeitsmedizin Augenheilkunde Chirurgie Dermatologie Gynäkologie und Geburtshilfe HNO Innere Medizin Kardiologie Neurologie Onkologie und Hämatologie Orthopädie und Unfallchirurgie Pädiatrie Pathologie Psychiatrie Radiologie Rechtsmedizin Urologie Zahnmedizin
Themen
Klimawandel und Gesundheit Neues aus dem Markt COVID-19 Praxis und Beruf Seltene Erkrankungen GOÄ & EBM Panorama
Sammlungen
Kasuistiken Algorithmen & Infografiken Blickdiagnosen Arthropedia FlapFinder (für Dermatochirurgen) Videos Kongressberichterstattung Medizin für Apothekerinnen und Apotheker Für Ärztinnen und Ärzte in Weiterbildung Für Medizinstudierende
Erweiterte Suche
Anmelden
nach oben
Current Oncology Reports
Erschienen in: Current Oncology Reports 12/2019

01.12.2019 | Neuro-oncology (Y Umemura, Section Editor)

Neurologic Immune-Related Adverse Events Associated with Immune Checkpoint Inhibition

verfasst von: Peter Chei-way Pan, Aya Haggiagi

Erschienen in: Current Oncology Reports | Ausgabe 12/2019

Einloggen, um Zugang zu erhalten

Abstract

Purpose of Review

This review highlights the spectrum of neurologic adverse events seen with use of immune checkpoint inhibitors (ICIs), their potential mechanisms, the treatments undertaken, and the clinical outcomes.

Recent Findings

The advent of ICIs has revolutionized cancer therapy. Neurologic adverse events (NAEs) are rare but clinically significant complication of ICIs. They can involve both the central and peripheral nervous system. Examples include myositis, neuropathy, encephalopathy, and myasthenia gravis. Treatment consists of holding the ICI, administration of corticosteroids, and other immunomodulatory agents as needed. The outcomes are generally favorable; however, rarely severe events can lead to significant morbidity and even mortality.

Summary

Identifying and treating the range of neurologic adverse events that may potentially arise with ICIs is very important as the oncologic indications for their use continues to expand.
Literatur
1.
Hodi FS, O’Day SJ, McDermott DF, Weber RW, Sosman JA, Haanen JB, et al. Improved survival with ipilimumab in patients with metastatic melanoma. N Engl J Med. 2010;363(8):711–23.PubMedPubMedCentralCrossRef
2.
Weber JS, D’Angelo SP, Minor D, Hodi FS, Gutzmer R, Neyns B, et al. Nivolumab versus chemotherapy in patients with advanced melanoma who progressed after anti-CTLA-4 treatment (CheckMate 037): a randomised, controlled, open-label, phase 3 trial. Lancet Oncol. 2015;16(4):375–84.PubMedCrossRef
3.
Borghaei H, Paz-Ares L, Horn L, Spigel DR, Steins M, Ready NE, et al. Nivolumab versus docetaxel in advanced nonsquamous non–small-cell lung cancer. N Engl J Med. 2015;373(17):1627–39.PubMedPubMedCentralCrossRef
4.
Ferris RL, Blumenschein G, Fayette J, Guigay J, Colevas AD, Licitra L, et al. Nivolumab for recurrent squamous-cell carcinoma of the head and neck. N Engl J Med. 2016;375(19):1856–67.PubMedPubMedCentralCrossRef
5.
Kang Y-K, Boku N, Satoh T, Ryu M-H, Chao Y, Kato K, et al. Nivolumab in patients with advanced gastric or gastro-oesophageal junction cancer refractory to, or intolerant of, at least two previous chemotherapy regimens (ONO-4538-12, ATTRACTION-2): a randomised, double-blind, placebo-controlled, phase 3 trial. Lancet. 2017;390(10111):2461–71.PubMedCrossRef
6.
Motzer RJ, Escudier B, McDermott DF, George S, Hammers HJ, Srinivas S, et al. Nivolumab versus everolimus in advanced renal-cell carcinoma. N Engl J Med. 2015;373(19):1803–13.PubMedPubMedCentralCrossRef
7.
Bellmunt J, de Wit R, Vaughn DJ, Fradet Y, Lee J-L, Fong L, et al. Pembrolizumab as second-line therapy for advanced urothelial carcinoma. N Engl J Med. 2017;376(11):1015–26.PubMedPubMedCentralCrossRef
8.
Spain L, Diem S, Larkin J. Management of toxicities of immune checkpoint inhibitors. Cancer Treat Rev. 2016;44:51–60.PubMedCrossRef
9.
Eltobgy M, Oweira H, Petrausch U, Helbling D, Schmidt J, Mehrabi A, et al. Immune-related neurological toxicities among solid tumor patients treated with immune checkpoint inhibitors: a systematic review. Expert Rev Neurother. 2017;17(7):725–36.PubMedCrossRef
10.
Schadendorf D, Wolchok JD, Hodi FS, Chiarion-Sileni V, Gonzalez R, Rutkowski P, et al. Efficacy and safety outcomes in patients with advanced melanoma who discontinued treatment with nivolumab and Ipilimumab because of adverse events: a pooled analysis of randomized phase II and III trials. J Clin Oncol. 2017;35(34):3807–14.PubMedPubMedCentralCrossRef
11.
Wick W, Hertenstein A, Platten M. Neurological sequelae of cancer immunotherapies and targeted therapies. Lancet Oncol. 2016;17(12):e529–41.PubMedCrossRef
12.
Mandel JJ, Olar A, Aldape KD, Tremont-Lukats IW. Lambrolizumab induced central nervous system (CNS) toxicity. J Neurol Sci. 2014 Sep;344(1–2):229–31.PubMedPubMedCentralCrossRef
13.
Lanfranchi M, Lee EQ, Buchbinder E, DeWitt J, Mehan WA. Pembrolizumab-related neuroinflammation: a case report and review of the literature. Neurographics. 2018;8(2):119–23.CrossRef
14.
Jenkins MK. Antigen presentation by chemically modified splenocytes induces antigen-specific T cell unresponsiveness in vitro and in vivo. J Exp Med. 1987;165(2):302–19.PubMedCrossRef
15.
Yshii LM, Hohlfeld R, Liblau RS. Inflammatory CNS disease caused by immune checkpoint inhibitors: status and perspectives. Nat Rev Neurol. 2017;13(12):755–63.PubMedCrossRef
16.
Gibson HM, Hedgcock CJ, Aufiero BM, Wilson AJ, Hafner MS, Tsokos GC, et al. Induction of the CTLA-4 gene in human lymphocytes is dependent on NFAT binding the proximal promoter. J Immunol. 2007;179(6):3831–40.PubMedCrossRef
17.
Zheng Y, Josefowicz SZ, Kas A, Chu T-T, Gavin MA, Rudensky AY. Genome-wide analysis of Foxp3 target genes in developing and mature regulatory T cells. Nature. 2007;445(7130):936–40.PubMedCrossRef
18.
Yokosuka T, Takamatsu M, Kobayashi-Imanishi W, Hashimoto-Tane A, Azuma M, Saito T. Programmed cell death 1 forms negative costimulatory microclusters that directly inhibit T cell receptor signaling by recruiting phosphatase SHP2. J Exp Med. 2012;209(6):1201–17.PubMedPubMedCentralCrossRef
19.
Granier C, De Guillebon E, Blanc C, Roussel H, Badoual C, Colin E, et al. Mechanisms of action and rationale for the use of checkpoint inhibitors in cancer. ESMO Open. 2017;2(2):e000213.PubMedPubMedCentralCrossRef
20.
21.
Maeda O, Yokota K, Atsuta N, Katsuno M, Akiyama M, Ando Y. Nivolumab for the treatment of malignant melanoma in a patient with pre-existing myasthenia gravis. Nagoya J Med Sci. 2016;78(1):119–22.PubMedPubMedCentral
22.
23.
Johnson DB, Sullivan RJ, Ott PA, Carlino MS, Khushalani NI, Ye F, et al. Ipilimumab therapy in patients with advanced melanoma and preexisting autoimmune disorders. JAMA Oncol. 2016;2(2):234–40.PubMedCrossRef
24.
Sato K, Akamatsu H, Murakami E, Sasaki S, Kanai K, Hayata A, et al. Correlation between immune-related adverse events and efficacy in non-small cell lung cancer treated with nivolumab. Lung Cancer. 2018;115:71–4.PubMedCrossRef
25.
Arriola E, Wheater M, Galea I, Cross N, Maishman T, Hamid D, et al. Outcome and biomarker analysis from a multicenter phase 2 study of ipilimumab in combination with carboplatin and etoposide as first-line therapy for extensive-stage SCLC. J Thorac Oncol. 2016;11(9):1511–21. PubMedPubMedCentralCrossRef
26.
27.
•• Zhao J, Chen AX, Gartrell RD, Silverman AM, Aparicio L, Chu T, et al. Immune and genomic correlates of response to anti-PD-1 immunotherapy in glioblastoma. Nat Med. 2019;25(3):462–9. Recent elegant analysis into the factors underlying responsiveness to checkpoint inhibition in glioblastoma. PubMedPubMedCentralCrossRef
28.
Tran E, Ahmadzadeh M, Lu Y-C, Gros A, Turcotte S, Robbins PF, et al. Immunogenicity of somatic mutations in human gastrointestinal cancers. Science. 2015;350(6266):1387–90.PubMedPubMedCentralCrossRef
29.
Łuksza M, Riaz N, Makarov V, Balachandran VP, Hellmann MD, Solovyov A, et al. A neoantigen fitness model predicts tumour response to checkpoint blockade immunotherapy. Nature. 2017;551(7681):517–20.PubMedPubMedCentralCrossRef
30.
Australian Pancreatic Cancer Genome Initiative, Balachandran VP, Łuksza M, Zhao JN, Makarov V, Moral JA, et al. Identification of unique neoantigen qualities in long-term survivors of pancreatic cancer. Nature. 2017;551(7681):512–6.PubMedCentralCrossRef
31.
Weiss MD, Luciano CA, Semino-Mora C, Dalakas MC, Quarles RH. Molecular mimicry in chronic inflammatory demyelinating polyneuropathy and melanoma. Neurology. 1998;51(6):1738–41.PubMedCrossRef
32.
Tsuchida T, Saxton RE, Morton DL, Irie RF. Gangliosides of human melanoma. J Natl Cancer Inst. 1987;78(1):45–54.PubMedCrossRef
33.
Gerdes LA, Held K, Beltrán E, Berking C, Prinz JC, Junker A, et al. CTLA4 as immunological checkpoint in the development of multiple sclerosis: CTLA4 and MS. Ann Neurol. 2016;80(2):294–300.PubMedPubMedCentralCrossRef
34.
•• Kao JC, Liao B, Markovic SN, Klein CJ, Naddaf E, Staff NP, et al. Neurological complications associated with anti-programmed death 1 (PD-1) antibodies. JAMA Neurology. 2017;74(10):1216. One of the largest retrospective cohorts of NAEs from the Mayo Clinic.PubMedPubMedCentralCrossRef
35.
•• Cuzzubbo S, Javeri F, Tissier M, Roumi A, Barlog C, Doridam J, et al. Neurological adverse events associated with immune checkpoint inhibitors: review of the literature. Eur J Cancer. 2017;73:1–8. One of the largest reviews of NAEs previously reported in case reports and series. PubMedCrossRef
36.
37.
Lynch TJ, Bondarenko I, Luft A, Serwatowski P, Barlesi F, Chacko R, et al. Ipilimumab in combination with paclitaxel and carboplatin as first-line treatment in stage IIIB/IV non–small-cell lung cancer: results from a randomized, double-blind, multicenter phase II study. J Clin Oncol. 2012;30(17):2046–54.PubMedCrossRef
38.
Brahmer J, Reckamp KL, Baas P, Crinò L, Eberhardt WEE, Poddubskaya E, et al. Nivolumab versus docetaxel in advanced squamous-cell non-small-cell lung cancer. N Engl J Med. 2015;373(2):123–35.PubMedPubMedCentralCrossRef
39.
Horinouchi H, Yamamoto N, Fujiwara Y, Sekine I, Nokihara H, Kubota K, et al. Phase I study of ipilimumab in phased combination with paclitaxel and carboplatin in Japanese patients with non-small-cell lung cancer. Investig New Drugs. 2015;33(4):881–9.CrossRef
40.
McDermott DF, Drake CG, Sznol M, Choueiri TK, Powderly JD, Smith DC, et al. Survival, durable response, and long-term safety in patients with previously treated advanced renal cell carcinoma receiving nivolumab. J Clin Oncol. 2015;33(18):2013–20.PubMedPubMedCentralCrossRef
41.
Robert C, Ribas A, Wolchok JD, Hodi FS, Hamid O, Kefford R, et al. Anti-programmed-death-receptor-1 treatment with pembrolizumab in ipilimumab-refractory advanced melanoma: a randomised dose-comparison cohort of a phase 1 trial. Lancet. 2014;384(9948):1109–17.PubMedCrossRef
42.
Kartolo A, Sattar J, Sahai V, Baetz T, Lakoff JM. Predictors of immunotherapy-induced immune-related adverse events. Curr Oncol. 2018;2:25(5).
43.
Du Four S, Hong A, Chan M, Charakidis M, Duerinck J, Wilgenhof S, et al. Symptomatic histologically proven necrosis of brain following stereotactic radiation and Ipilimumab in six lesions in four melanoma patients. Case Rep Oncol Med. 2014;2014:1–6.
44.
Barker CA, Postow MA, Khan SA, Beal K, Parhar PK, Yamada Y, et al. Concurrent radiotherapy and Ipilimumab immunotherapy for patients with melanoma. Cancer Immunol Res. 2013;1(2):92–8.PubMedPubMedCentralCrossRef
45.
Kao JC, Brickshawana A, Liewluck T. Neuromuscular complications of programmed cell death-1 (PD-1) inhibitors. Current Neurology and Neuroscience Reports. 2018;18(10).
46.
Conry RM, Sullivan JC, Nabors LB. Ipilimumab-induced encephalopathy with a reversible splenial lesion. Cancer Immunol Res. 2015;3(6):598–601.PubMedCrossRef
47.
Salam S, Lavin T, Turan A. Limbic encephalitis following immunotherapy against metastatic malignant melanoma. BMJ Case Rep. 2016;bcr2016215012.
48.
Zurko J, Mehta A. Association of immune-mediated cerebellitis with immune checkpoint inhibitor therapy. Mayo Clin Proc Innov Qual Outcomes. 2018;2(1):74–7.PubMedPubMedCentralCrossRef
49.
Vitt JR, Kreple C, Mahmood N, Dickerson E, Lopez GY, Richie MB. Autoimmune pancerebellitis associated with pembrolizumab therapy. Neurology. 2018;91(2):91–3.PubMedPubMedCentralCrossRef
50.
Williams TJ, Benavides DR, Patrice K-A, Dalmau JO, de Ávila ALR, Le DT, et al. Association of autoimmune encephalitis with combined immune checkpoint inhibitor treatment for metastatic cancer. JAMA Neurol. 2016;73(8):928.PubMedCrossRef
51.
Larkin J, Chmielowski B, Lao CD, Hodi FS, Sharfman W, Weber J, et al. Neurologic serious adverse events associated with nivolumab plus ipilimumab or nivolumab alone in advanced melanoma, including a case series of encephalitis. Oncologist. 2017;22(6):709–18.PubMedPubMedCentralCrossRef
52.
Astaras C, de Micheli R, Moura B, Hundsberger T, Hottinger AF. Neurological adverse events associated with immune checkpoint inhibitors: diagnosis and management. Curr Neurol Neurosci Rep. 2018;18(1).
53.
Brown MP, Hissaria P, Hsieh AH, Kneebone C, Vallat W. Autoimmune limbic encephalitis with anti-contactin-associated protein-like 2 antibody secondary to pembrolizumab therapy. J Neuroimmunol. 2017;305:16–8.PubMedCrossRef
54.
Roberts P, Fishman GA, Joshi K, Jampol LM. Chorioretinal lesions in a case of melanoma-associated retinopathy treated with pembrolizumab. JAMA Ophthalmol. 2016;134(10):1184–8.PubMedCrossRef
55.
Maurice C, Schneider R, Kiehl T-R, Bavi P, Roehrl MHA, Mason WP, et al. Subacute CNS demyelination after treatment with nivolumab for melanoma. Cancer Immunology Research. 2015;3(12):1299–302.PubMedCrossRef
56.
Cao Y, Nylander A, Ramanan S, Goods BA, Ponath G, Zabad R, et al. CNS demyelination and enhanced myelin-reactive responses after ipilimumab treatment. Neurology. 2016;86(16):1553–6.PubMedPubMedCentralCrossRef
57.
Gettings EJ, Hackett CT, Scott TF. Severe relapse in a multiple sclerosis patient associated with ipilimumab treatment of melanoma. Mult Scler J. 2015;21(5):670.CrossRef
58.
Wilson MA, Guld K, Galetta S, Walsh RD, Kharlip J, Tamhankar M, et al. Acute visual loss after ipilimumab treatment for metastatic melanoma. J Immunother Cancer. 2016;4(1).
59.
Yeh OL, Francis CE. Ipilimumab-associated bilateral optic neuropathy. J Neuroophthalmol. 2015;35(2):144–7.PubMedCrossRef
60.
Khoja L, Maurice C, Chappell M, MacMillan L, Al-Habeeb AS, Al-Faraidy N, et al. Eosinophilic fasciitis and acute encephalopathy toxicity from pembrolizumab treatment of a patient with metastatic melanoma. Cancer Immunology Research. 2016;4(3):175–8.PubMedCrossRef
61.
Läubli H, Hench J, Stanczak M, Heijnen I, Papachristofilou A, Frank S, et al. Cerebral vasculitis mimicking intracranial metastatic progression of lung cancer during PD-1 blockade. Journal for ImmunoTherapy of Cancer. 2017;5(1).
62.
Dunn-Pirio AM, Shah S, Eckstein C. Neurosarcoidosis following immune checkpoint inhibition. Case Rep Oncol. 2018;27:521–6.CrossRef
63.
Liao B, Shroff S, Kamiya-Matsuoka C, Tummala S. Atypical neurological complications of ipilimumab therapy in patients with metastatic melanoma. Neuro-Oncology. 2014;16(4):589–93.PubMedPubMedCentralCrossRef
64.
O’Kane GM, Lyons TG, Colleran GC, Ahmad MW, Alken S, Kavanagh EC, et al. Late-onset paraplegia after complete response to two cycles of ipilimumab for metastatic melanoma. Oncol Res Treat. 2014;37(12):757–60.PubMedCrossRef
65.
Bompaire F, Mateus C, Taillia H, De Greslan T, Lahutte M, Sallansonnet-Froment M, et al. Severe meningo-radiculo-neuritis associated with ipilimumab. Investig New Drugs. 2012;30(6):2407–10.CrossRef
66.
de Maleissye M-F, Nicolas G, Saiag P. Pembrolizumab-induced demyelinating polyradiculoneuropathy. N Engl J Med. 2016;375(3):296–7.PubMedCrossRef
67.
•• Chen X, Haggiagi A, Tzatha E, DeAngelis LM, Santomasso B. Electrophysiological findings in immune checkpoint inhibitor-related peripheral neuropathy. Clin Neurophysiol. 2019;130(8):1440–5. Large and detailed study focusing on ICI-related neuropath and its electrophysiologic correlates. PubMedPubMedCentralCrossRef
68.
Fukumoto Y, Kuwahara M, Kawai S, Nakahama K, Kusunoki S. Acute demyelinating polyneuropathy induced by nivolumab. J Neurol Neurosurg Psychiatry. 2018;89(4):435–7.PubMedCrossRef
69.
Aya F, Ruiz-Esquide V, Viladot M, Font C, Prieto-Gonzalez S, Prat A, et al. Vasculitic neuropathy induced by pembrolizumab. Ann Oncol. 2016;28(2):433–4.CrossRef
70.
Altman AL, Golub JS, Pensak ML, Samy RN. Bilateral facial palsy following ipilimumab infusion for melanoma. Otolaryngol Head Neck Surg. 2015;153(5):894–5.PubMedCrossRef
71.
72.
Dubey D, David WS, Amato AA, Reynolds KL, Clement NF, Chute DF, et al. Varied phenotypes and management of immune checkpoint inhibitor-associated neuropathies. Neurology. 2019;93(11):e1093–103.PubMedCrossRef
73.
Manousakis G, Koch J, Sommerville RB, El-Dokla A, Harms MB, Al-Lozi MT, et al. Multifocal radiculoneuropathy during ipilimumab treatment of melanoma: ipilimumab radiculoneuropathy. Muscle Nerve. 2013;48(3):440–4.PubMedCrossRef
74.
Jinnur P, Lim KG. Severe acute orthopnea: ipilimumab-induced bilateral phrenic nerve neuropathy. Lung. 2015;193(4):611–3.PubMedCrossRef
75.
Supakornnumporn S, Katirji B. Guillain–Barre’ syndrome triggered by immune checkpoint inhibitors: a case report and literature review. J Clin Neuromuscul Dis. 2017;19(2):4.CrossRef
76.
Jacob A, Unnikrishnan DC, Mathew A, Thyagarajan B, Patel S. A case of fatal Guillain–Barre syndrome from anti-PD1 monoclonal antibody use. J Cancer Res Clin Oncol. 2016;142(8):1869–70.PubMedCrossRef
77.
Gaudy-Marqueste C, Monestier S, Franques J, Richard M-A, Grob J-J. A severe case of ipilimumab-induced Guillain-Barre’ syndrome revealed by an occlusive enteric neuropathy: a differential diagnosis for ipilimumab-induced colitis. J Immunother. 2013;36(1):77–8.PubMedCrossRef
78.
Wilgenhof S, Neyns B. Anti-CTLA-4 antibody-induced Guillain-Barre syndrome in a melanoma patient. Ann Oncol. 2011;22(4):991–3.PubMedCrossRef
79.
Hottinger AF. Neurologic complications of immune checkpoint inhibitors: current opinion in neurology. Curr Opin Neurol. 2016;29(6):806–12.PubMedCrossRef
80.
Kolb NA, Trevino CR, Waheed W, Sobhani F, Landry KK, Thomas AA, et al. Neuromuscular complications of immune checkpoint inhibitor therapy. Muscle Nerve. 2018;58(1):10–22.CrossRef
81.
Green KE, Levine AM, Ward JH, Kaufman DI. GQ1b-Seronegative miller fisher syndrome associated with pembrolizumab. J Neuroophthalmol. 2019;39(3):394–6.PubMedCrossRef
82.
Kang KH, Grubb W, Sawlani K, Gibson MK, Hoimes CJ, Rogers LR, et al. Immune checkpoint-mediated myositis and myasthenia gravis: a case report and review of evaluation and management. Am J Otolaryngol. 2018;39(5):642–5.PubMedCrossRef
83.
Huh S-Y, Shin S-H, Kim MK, Lee S-Y, Son KH, Shin HY. Emergence of myasthenia gravis with myositis in a patient treated with pembrolizumab for thymic cancer. J Clin Neurol. 2018;14(1):115–7.PubMedCrossRef
84.
Chen Y-H, Liu F-C, Hsu C-H, Chian C-F. Nivolumab-induced myasthenia gravis in a patient with squamous cell lung carcinoma: case report. Medicine. 2017;96(27):e7350.PubMedPubMedCentralCrossRef
85.
Chen J-H, Lee K-Y, Hu C-J, Chung C-C. Coexisting myasthenia gravis, myositis, and polyneuropathy induced by ipilimumab and nivolumab in a patient with non-small-cell lung cancer: a case report and literature review. Medicine. 2017;96(50):e9262.PubMedPubMedCentralCrossRef
86.
Hibino M, Maeda K, Horiuchi S, Fukuda M, Kondo T. Pembrolizumab-induced myasthenia gravis with myositis in a patient with lung cancer: pembrolizumab-induced myasthenia gravis. Respirology Case Reports. 2018;6(7):e00355.PubMedPubMedCentralCrossRef
87.
Mehta JJ, Maloney E, Srinivasan S, Seitz P, Cannon M. Myasthenia gravis induced by nivolumab: a case report. Cureus. 2017;20.
88.
Shirai T, Sano T, Kamijo F, Saito N, Miyake T, Kodaira M, et al. Acetylcholine receptor binding antibody-associated myasthenia gravis and rhabdomyolysis induced by nivolumab in a patient with melanoma. Jpn J Clin Oncol. 2016;46(1):86–8.PubMedCrossRef
89.
Johnson DB, Balko JM, Compton ML, Chalkias S, Gorham J, Xu Y, et al. Fulminant myocarditis with combination immune checkpoint blockade. N Engl J Med. 2016;375(18):1749–55.PubMedPubMedCentralCrossRef
90.
Moslehi JJ, Salem J-E, Sosman JA, Lebrun-Vignes B, Johnson DB. Increased reporting of fatal immune checkpoint inhibitor-associated myocarditis. Lancet. 2018;391(10124):933.PubMedPubMedCentralCrossRef
91.
Kimura T, Fukushima S, Miyashita A, Aoi J, Jinnin M, Kosaka T, et al. Myasthenic crisis and polymyositis induced by one dose of nivolumab. Cancer Sci. 2016;107(7):1055–8.PubMedPubMedCentralCrossRef
92.
Makarious D, Horwood K, Coward JIG. Myasthenia gravis: an emerging toxicity of immune checkpoint inhibitors. Eur J Cancer. 2017;82:128–36.PubMedCrossRef
93.
Algaeed M, Mukharesh L, Heinzelmann M, Kaminski HJ. Pearls & Oy-sters: pembrolizumab-induced myasthenia gravis. Neurology. 2018;91(14):e1365–7.PubMedCrossRef
94.
Tan RYC, Toh CK, Takano A. Continued response to one dose of nivolumab complicated by myasthenic crisis and myositis. J Thorac Oncol. 2017;12(7):e90–1.PubMedCrossRef
95.
Gonzalez NL, Puwanant A, Lu A, Marks SM, Živković SA. Myasthenia triggered by immune checkpoint inhibitors: new case and literature review. Neuromuscul Disord. 2017;27(3):266–8.PubMedCrossRef
96.
Bilen MA, Subudhi SK, Gao J, Tannir NM, Tu S-M, Sharma P. Acute rhabdomyolysis with severe polymyositis following ipilimumab-nivolumab treatment in a cancer patient with elevated anti-striated muscle antibody. Journal for ImmunoTherapy of Cancer. 2016;4(1).
97.
98.
Champiat S, Lambotte O, Barreau E, Belkhir R, Berdelou A, Carbonnel F, et al. Management of immune checkpoint blockade dysimmune toxicities: a collaborative position paper. Ann Oncol. 2016;27(4):559–74.PubMedCrossRef
99.
Brahmer JR, Lacchetti C, Schneider BJ, Atkins MB, Brassil KJ, Caterino JM, et al. Management of immune-related adverse events in patients treated with immune checkpoint inhibitor therapy: American Society of Clinical Oncology clinical practice guideline. J Clin Oncol. 2018;36(17):1714–68.PubMedCrossRef
100.
Schneider S, Potthast S, Komminoth P, Schwegler G, Böhm S. PD-1 checkpoint inhibitor associated autoimmune encephalitis. Case Rep Oncol. 2017;10(2):473–8.PubMedPubMedCentralCrossRef
101.
Bossart S, Thurneysen S, Rushing E, Frontzek K, Leske H, Mihic-Probst D, et al. Case report: encephalitis, with brainstem involvement, following checkpoint inhibitor therapy in metastatic melanoma. Oncologist. 2017;22(6):749–53.PubMedPubMedCentralCrossRef
102.
Leitinger M, Varosanec MV, Pikija S, Wass RE, Bandke D, Weis S, et al. Fatal necrotizing encephalopathy after treatment with Nivolumab for squamous non-small cell lung cancer: case report and review of the literature. Front Immunol. 2018;30:9.
103.
Eggermont AMM, Chiarion-Sileni V, Grob J-J, Dummer R, Wolchok JD, Schmidt H, et al. Prolonged survival in stage III melanoma with Ipilimumab adjuvant therapy. N Engl J Med. 2016;375(19):1845–55.PubMedPubMedCentralCrossRef
104.
Johnson DB, Saranga-Perry V, Lavin PJM, Burnette WB, Clark SW, Uskavitch DR, et al. Myasthenia gravis induced by ipilimumab in patients with metastatic melanoma. J Clin Oncol. 2015;33(33):e122–4.PubMedPubMedCentralCrossRef
Metadaten
Titel
Neurologic Immune-Related Adverse Events Associated with Immune Checkpoint Inhibition
verfasst von
Peter Chei-way Pan
Aya Haggiagi
Publikationsdatum
01.12.2019
Verlag
Springer US
Erschienen in
Current Oncology Reports / Ausgabe 12/2019
Print ISSN: 1523-3790
Elektronische ISSN: 1534-6269
DOI
https://doi.org/10.1007/s11912-019-0859-2

Weitere Artikel der Ausgabe 12/2019

Current Oncology Reports 12/2019 Zur Ausgabe

Palliative Medicine (A Jatoi, Section Editor)

The Role of Ablation in Cancer Pain Relief

Melanoma (RJ Sullivan, Section Editor)

Primary Melanoma: from History to Actual Debates

Melanoma (RJ Sullivan, Section Editor)

The Evolution of Adjuvant Therapy for Melanoma

Breast Cancer (B Overmoyer, Section Editor)

When to Add Additional Anti-HER2 Therapy to Adjuvant Trastuzumab

Lung Cancer (H Borghaei, Section Editor)

Poor-Performance Status Assessment of Patients with Non-small Cell Lung Cancer Remains Vague and Blurred in the Immunotherapy Era

Breast Cancer (B Overmoyer, Section Editor)

When Can We Avoid Postmastectomy Radiation Following Primary Systemic Therapy?

Neu im Fachgebiet Onkologie

16.04.2024 | Maligne primäre ZNS-Tumoren | Nachrichten

Manche Gestagene können das Risiko für Meningeome erhöhen

10.04.2024 | PSA-Screening | Nachrichten

Einladung zum PSA-Screening senkt die Krebssterblichkeit

09.04.2024 | DGP 2024 | Kongressbericht | Nachrichten

Chemotherapie mit Hindernissen

09.04.2024 | Mammakarzinom | Nachrichten

Das Ende der vollständigen axillären Lymphknotendissektion
weitere anzeigen

Update Onkologie

Bestellen Sie unseren Fach-Newsletter und bleiben Sie gut informiert.

Newsletter bestellen